DD6 Toxicity and Drug Safety

Updated

Drug safety remains the primary cause of compound attrition when developing new medicines and consequently the ability to understand and predict toxicity is regarded as high priority within the pharmaceutical sector. This lecture will describe some common safety liabilities and ongoing work to build a greater understanding of the relationships between chemical structure and toxicity risk that are being harnessed to guide the design of safer compounds

Dr R Ian Storer - AstraZeneca

Number of sessions: 1